Exercise of Share Options and Total Voting Rights | 10-Jul-2023 | 07:00 | RNS |
Director/PDMR Shareholding | 26-Jun-2023 | 07:00 | RNS |
Holding(s) in Company | 22-Jun-2023 | 16:01 | RNS |
Exercise of Share Options and Total Voting Rights | 16-Jun-2023 | 07:00 | RNS |
Holding(s) in Company | 14-Jun-2023 | 16:10 | RNS |
Exercise of Share Options and Total Voting Rights | 06-Jun-2023 | 17:00 | RNS |
Analyst and Investor presentation | 05-Jun-2023 | 10:00 | RNS |
FDA De Novo approval | 05-Jun-2023 | 07:00 | RNS |
Issue of Equity | 28-Mar-2023 | 11:30 | RNS |
Successful submission of additional data to US FDA | 27-Mar-2023 | 07:00 | RNS |
Second Price Monitoring Extn | 14-Mar-2023 | 14:05 | RNS |
Price Monitoring Extension | 14-Mar-2023 | 14:00 | RNS |
Issue of Equity | 14-Mar-2023 | 09:30 | RNS |
Issue of Equity | 22-Feb-2023 | 16:30 | RNS |
Half-year Report | 20-Feb-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 440.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 485.00 |
52 Week Low | 327.50 |
Volume | 22,772 |
Shares Issued | 47.54m |
Market Cap | £209.16m |
RiskGrade | 180 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 2 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 21-Mar-24 | 23-Nov-23 |
Paid | 12-Apr-24 | 22-Dec-23 |
Amount | 5.24p | 7.88p |
Time | Volume / Share Price |
16:18 | 2 @ 447.00p |
15:48 | 898 @ 440.00p |
15:38 | 706 @ 431.55p |
15:11 | 5,406 @ 431.00p |
14:37 | 1 @ 441.00p |
CEO | Paul Christopher Swinney |
Finance Director | Elizabeth Dixon |
You are here: research